Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor

NCT01344707 is registered in ClinicalTrials.gov with 4SC AG as lead sponsor.

NCT NCT01344707
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01344707 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Label, Dose Escalation Study of 4SC-202 in Patients With Advanced Hematologic Malignancies: First-In-Man Study of a Newly Developed, Oral Histone Deacetylase Inhibitor
Lead sponsor
4SC AG
Phase
Phase 1
Overall status
Completed
Start date
March 31, 2011
Completion date
March 31, 2015
Enrollment
36 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

advanced hematologic malignancies